BioWorld Asia

Jan. 31, 2007

Faith In Bio Market Pays Off With Europe's Largest Fund

LONDON - Abingworth Management closed Europe's largest ever life sciences venture fund, Abingworth Bioventures V, capping the oversubscribed fund at £300 million (US$586.9 million). (BioWorld International) Read More

GPC Biotech Banks $44M Toward Satraplatin Launch

Sleep-Inducing Drug Strategy Promises Some Sweet Dreams

Avesthagen Closes €25M Round, Proclaims Leadership In India

No Abstract Read More

Cellectis Launches IPO, Seeking €16M to €21M

No Abstract Read More

Anglo-Australian Partnership Seeks New Cancer Therapies

New Ethics Warning Issued On Nanomedicine In Europe

Plant Biotech Expert Attacks 'Dysfunctional' Regulations

Other News To Note

Today's news in brief

BioWorld

BioWorld briefs for July 8, 2026.

Illustration of brain and brain waves, concept of focal seizure

Hyperexcitability may be joint problem in epilepsy, dementia

BioWorld

The majority of epilepsies are developmental disorders that start in childhood. But there is a large minority that starts in late adulthood. And increasingly,...

3D rendering of an antibody drug conjugate

‘Target-high but uptake-defective’ state identified in ADC resistance

BioWorld

Separate research teams have reported new insights into resistance mechanisms to the antibody-drug conjugate (ADC) Padcev (enfortumab vedotin, Astellas Pharma...

Modius Spero wearable neuromodulation device

Neurovalens granted FDA approval for PTSD therapy for US veterans

BioWorld

Veterans in the U.S. suffering from post-traumatic stress disorder (PTSD) now have access to Neurovalens Ltd.’s Modius Spero, a wearable neuromodulation device,...

In the clinic for July 6, 2026

BioWorld

Clinical updates for biopharma and med tech, including data readouts and publications: Arcus, Genentech, Merck, Myriad, Otsuka, Partner, Revolution, Treos.